Lobbying Information
Subject Matters
- Consumer Issues
- Health
- Industry
- Intellectual Property
- Internal Trade
- International Relations
- International Trade
- Science and Technology
- Small Business
- Taxation and Finance
Subject Matter Details
Legislative Proposal, Bill or Resolution
- Provide input into the Government of Canada's negotiations regarding the Anti-Counterfeiting Trade Agreement and bilateral trade agreements with respect to pharmaceuticals, counterfeit medicines, and intellectual property.
- Provide input into the Government of Canada's negotiations regarding the Canada-European Union Comprehensive Economic Trade Agreement with respect to pharmaceuticals, counterfeit medicines, border measures, and intellectual property.
Policies or Program
- Health Canada and Finance Canada regarding the need for appropriate and dedicated resources for the Therapeutic Products Directorate to ensure performance targets are met for the review of generic drug submissions.
- Health Canada regarding a need for effective implementation of the National Pharmaceuticals Strategy by federal and provincial governments.
- Improvements to Canada's Access to Medicines Regime to ensure access by developing and least developed global regions to Canadian manufactured generic pharmaceuticals in times of health crises.
- Industry Canada's Science & Technology strategy regarding the need for a balanced intellectual property regime and the important role competition plays in encouraging innovation.
- Patented Medicine Prices Review Board regarding claims of jurisdiction with respect to generic drug products associated with a patent.
- Proposals related to Health Canada's Identical Medicinal Ingredient Policy.
- Proposals to enhance transparency of the Health Canada Reconsiderations Policy for drug submissions
- Providing input into the development and implementation of an approval pathway for Subsequent Entry Biologics by Health Canada.
- Support for the finalization of the Health Canada Draft Guidance Documents: Conduct and Analysis of Comparative Bioavailability Studies and Comparative Bioavailability Standards: Formulations used for Systemic Effects.
- To encourage the Government of Canada to continue to participate in truly international discussions with respect to effective measures to combat counterfeit pharmaceutical both nationally and globally.
Regulation
- Health and Industry Canada regarding CGPA's legal challenge of the 2006 Amendments to Health Canada's Food and Drug Regulations with respect to Data Protection.
- The need for amendments to the Patented Medicines (Notice of Compliance) Regulations of the Patent Act and address operational concerns such as bringing finality to proceedings under the Regulations; allowing generic manufacturers to amend a Notice of Allegation; and providing meaningful damages and other disincentives to discourage abuse of the Regulatioins by brand name manufacturers.
Communication Techniques
-
Written communication
-
Oral communication
Government Institutions
-
Canadian Heritage (PCH)
-
Canadian International Development Agency (CIDA)
-
Canadian International Trade Tribunal (CITT)
-
Environment Canada
-
Finance Canada (FIN)
-
Foreign Affairs and International Trade Canada (DFAITC)
-
Hazardous Materials Information Review Commission (HMIRC)
-
Health Canada (HC)
-
House of Commons
-
Industry Canada
-
Natural Resources Canada (NRCan)
-
Patented Medicine Prices Review Board (PMPRB)
-
Prime Minister's Office (PMO)
-
Privy Council Office (PCO)
-
Public Health Agency of Canada (PHAC)
-
Revenue Canada (RC)
-
Senate of Canada
-
Treasury Board Of Canada Secretariat (TBS)
In-house Corporation Details
Description of activities
Provider of generic and specialty pharmaceuticals.
Responsible officer name and position during the period of this registration
Richard Guest,
Chief Executive Officer
Government funding
No government funding was received during the last completed financial year.
In-house Corporation Contact Information
Address:
85 Advance Road
Etobicoke, ON M8Z 2S6
Canada
Telephone number:
416-236-2631
Fax number:
416-236-9022
Parent Company Information
Mylan Pharmaceuticals ULC is not a subsidiary of any other parent companies.
Subsidiary Beneficiary Information
Mylan Pharmaceuticals ULC does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyists Details
Senior Officers whose lobbying activities represent less than 20% of their Duties
- Dawn Culp,
Senior Director, Regulatory Affairs |
No public offices held
- Bonnie Southorn,
Director, Regulatory Affairs |
No public offices held
Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties
- C. Benjamin Gray,
VP, Legal and General Counsel |
No public offices held
- Richard Guest,
Chief Executive Officer |
No public offices held
- Ian Hilley,
Vice President |
No public offices held
